Oral GLP-1 Agonists
7 articles on Oral GLP-1 Agonists, written by Shotlee and medically reviewed for clinical accuracy.
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
Oral GLP-1s: Orforglipron vs. Oral Wegovy Explained
The race for oral GLP-1 medications is intensifying, with Novo Nordisk's oral Wegovy now approved and Eli Lilly's orforglipron facing a brief FDA review extension. These pill-based alternatives to injections promise easier access for weight loss and metabolic health. Learn how they stack up in efficacy, tolerability, and real-world impact.
4 min read